A prominent theme in health-reform efforts is the need for more transparent information about healthcare cost and quality upon which providers and patients can base their treatment decisions. Many federal agencies and state governments are expanding their requirements for pharmaceutical companies to report payments made to researchers and physicians, and for health plans to give beneficiaries more information on drug costs and coverage.
Although there have been significant advances in prevention, diagnosis, treatment, and education, the occurrence of sexually transmitted diseases (STDs) continues to increase. This article focuses on the diagnosis and treatment of the most common STDs.
Generic drugs approved by FDA (through March 2009) including sumatriptan tablets, divalproex extended-release tablets, and risperidone oral solution
Recent FDA approvals (through March 2009) related to Gelnique, RiaSTAP, and Kapidex
Recent FDA action (through March 2009) related to cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, and omacetaxine
Ustekinumab is a novel investigational human monoclonal antibody (mAb) that is pending approval for the treatment of plaque psoriasis. Subcutaneous administration of ustekinumab has demonstrated efficacy in both phase 2 and 3 trials.
New formulation: Calcitriol (Vectical), a Vitamin D analogue, was approved on January 23, 2009, for the treatment of mild-to-moderate plaque psoriasis
New biologic: Antithrombin (recombinant) (ATryn), a recombinant human antithrombin, was approved on February 6, 2009, for the prevention of perioperative and peripartum thromboembolic events in hereditary antithrombin-deficient patients
Agents in late-stage development for the treatment of asthma, COPD, and PAH
The problems exposed in California reveal the need for focus on state rescission guidelines
Organizations need to use levers to build financial value for health investments
Performance registries are designed for data collection in reporting to CMS or potentially other payers
Insist that the expected value of improvements in information quality is expressed in dollar figures
The potential is there if you only seek the benefits
Some employers might need to adjust copay structures overall to achieve adequate compliance.
One way to level the playing field is to offer the public plan through an administered market system.
Payers have vast amounts of data that could be used in so many ways, if only HIPAA would allow it
Research must be actionable, relevant, timely, translated and transparent in its funding sources.
Key provisions include funding for Mediciad, COBRA subsidies, health records, NIH research, health centers, effectiveness research, and wellness programs.
Regina Herzlinger's prescription for reform calls for payment based on episodes of care.
Expected losses of delayed IT projects include improved quality, efficiency and care coordination
Your competitive edge can come from digitizing and automating labor-intensive processes to gain efficiencies
Commonwealth Fund State Performance Ranking (2007): 17
Federally qualified health centers need $248 million to meet plan targets, much more than the proposed $100 million in the appropriations bill
Group sessions can also empower patients to cope with recurrence of painful headaches
Sponsors of Part D legislation believe private Medicare Part D plans have been less effective than the government could be in negotiating price concessions.
Payment structure among stakeholders must be equitable in order to avoid contract disputes and provide the highest quality of care to consumers.
At a joint meeting of FDA's Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees on January 30, 2009, advisors voted 14 to 12 that propoxyphene and propoxyphene-containing products should be removed from the market. Propoxyphene (Darvon, Xanodyne; generic propoxyphene) and propoxyphene combinations, including Darvocet (Xanodyne), are used for the treatment of mild-to-moderate acute pain.
In an analysis of fracture risk associated with loop diuretic use among postmenopausal women in the Women's Health Initiative (WHI) study, investigators demonstrated no significant association between loop diuretic use and fractures or changes in bone mineral density (BMD). With prolonged use of loop diuretics, however, the risk of fracture was modestly increased.
Initial results of the Women's Health Initiative (WHI) study demonstrated an increased risk of breast cancer among postmenopausal women treated with estrogen plus progestin. A new long-term analysis of this study published in the New England Journal of Medicine demonstrated that breast cancer incidence decreased markedly after WHI study participants discontinued hormone therapy.
